Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Airbus’ 2025 was defined by scale and consistency, relying on the continued dominance of its narrowbody programs to take the ...

Across large population studies, people who live into their nineties and beyond keep showing up with the same quiet signature ...

Doctors often say labs look “normal.” Dr. Mark Hyman explains why that doesn’t always reflect wellness, and what early ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Understanding post-meal blood sugar is crucial for diabetes management, as food intake directly impacts glucose levels and insulin needs. While general target ranges exist, individual goals vary ...

We tested powders from Clean Simple Eats, Equate, Premier Protein, Ritual, and Truvani. Our results show it’s possible to ...

A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your ...

Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology.